Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ovarian Cancer Pipeline Review: Sponsors Plan Frontline Punch, Smart Combinations

Executive Summary

Combination studies of drugs for ovarian cancer have heavy focus on PARP, PD-1/L1 and VEGF mechanisms.

You may also be interested in...



ImmunoGen Needs Another Phase III For Its ADC In Ovarian Cancer

The biotech’s hopes for an accelerated approval on subgroup data were dashed by the US FDA, but it will work with the agency to design a Phase III focused on highly FRα-positive patients.

Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer

Interview: Tesaro Chief Medical Officer Martin Huber addresses dostarlimab GARNET data and provides an update on integration with GlaxoSmithKline.

Clinical Trials In Review: Big Hits And Misses In 2018

Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132082

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel